Ignite Creation Date:
2025-12-25 @ 2:27 AM
Ignite Modification Date:
2025-12-26 @ 1:01 AM
Study NCT ID:
NCT04207034
Status:
UNKNOWN
Last Update Posted:
2020-12-17
First Post:
2019-12-10
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Effect of the Diode Laser on Bacteremia Associated With Periodontal Flap Surgery: A Clinico-Microbiological Study
Sponsor:
Krishnadevaraya College of Dental Sciences & Hospital
Organization:
Study Overview
Official Title:
Effect of the Diode Laser on Bacteremia Associated With Periodontal Flap Surgery: A Clinico-Microbiological Study
Status:
UNKNOWN
Status Verified Date:
2020-12
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of the present study is
1. To study the incidence and magnitude of bacteremia after periodontal flap surgery .
2. To compare and evaluate the effect of diode laser on frequency of bacteremia associated with periodontal flap surgery .
3. To study the incidence of bacteremia after laser therapy
1. To study the incidence and magnitude of bacteremia after periodontal flap surgery .
2. To compare and evaluate the effect of diode laser on frequency of bacteremia associated with periodontal flap surgery .
3. To study the incidence of bacteremia after laser therapy
Detailed Description:
SOURCE OF DATA Patient visiting the Outpatient Section of the Department of Periodontology, Krishnadevaraya College of Dental Sciences and Hospital will be screened and randomly recruited for the study as per inclusion and exclusion criteria. The eligible subjects will be informed of the nature and benefits of the participation of the study and a written signed consent will be obtained. The study population will consist of twenty (n=20) subjects who will be age (30 to 40 years) and sex matched.
Sample Size The study was performed according to split- mouth design, and all teeth in the mouth were treated randomly using either the left or the right side of the maxilla and mandible for control , and the opposite side for the therapy. Each patient was entered into a clinical protocol consisting of two different treatment modalities.
Group I (n=10) - Test group ( diode laser + flap surgery) Group II (n=10) - control group (flap surgery)
SURGICAL PROCEDURE GROUP I (TEST GROUP) Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.
Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .
Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.
Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure.
GROUP II (CONTROL GROUP) Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .
Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.
Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure
Collection of blood samples Six millilitres (6 ml) of blood samples will be drawn from the patient through an antecubital vein using strict aseptic technique via a 22- gauge sterile plastic cannula and sent for for qPCR analysis to quantify total bacterial load.
PCR ANALYSIS The polymerase chain reaction (PCR) is a laboratory technique for DNA replication that allows the "target" DNA sequence to be selectively amplified. The PCR involves the primer mediated enzymatic amplification of DNA. In this study Quantitive polymerase chain reaction is done.
* DNA from the blood samples will be extracted using the QIAamp DNA Blood Mini Kit according to the manufacture's recommendations.
* In order to quantify the total bacterial load, qPCR will be carried out using a universal primer to the 16S ribosomal RNA gene.
* Analysis was performed in a total volume of 6 ml blood.
* Samples for qPCR will be dispensed into well plates, sealed and centrifuged.
* Amplification will be done , settings for qPCR will be as follows: 95 degree centigrade for 10 minutes followed by 40 amplification cycles at 95 degree centigrade for 1 minute, 52 degree centigrade for 1 minute , 72 degree centigrade for 1 minute.
* After each cycle , PCR products will be monitored for the increase in fluorescence of SYBR green.
* All measurements will be performed in triplicate for both test and controls.
* For the negative control , ultrapure water will be used replacing the clinical sample.
* To determine the specificity of the amplified products, a melting curve will be obtained from 60 degree centigrade to ninty five degree centigrade, with continuous florescence measurement at each 1% increase in temperature.
* Data acquisition and analysis will be performed using the ABI 7500 software.
Statistical analysis Data will be subjected for normality test. Best on the data parametric or non parametric test will be performed. P value \< 0.05 will be considered statistically significant.
Sample Size The study was performed according to split- mouth design, and all teeth in the mouth were treated randomly using either the left or the right side of the maxilla and mandible for control , and the opposite side for the therapy. Each patient was entered into a clinical protocol consisting of two different treatment modalities.
Group I (n=10) - Test group ( diode laser + flap surgery) Group II (n=10) - control group (flap surgery)
SURGICAL PROCEDURE GROUP I (TEST GROUP) Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1: 80,000 epinephrine) , Laser application will be carried out , with the help of 810 nm (A.R.C LASER FoxTM) diode laser with a flexible optic tip of 300µm . The sulci will be lased with a repeated beam ( 0.2 sec on 0.3 sec off) at an output power of 1.0 W.
Intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .
Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.
Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure.
GROUP II (CONTROL GROUP) Patient will be asked to rinse with 0.2% chlorhexidine mouthwash. Following the administration of local anaesthesia 2% lignocaine hydrochloride ( with 1:80,000 epinephrine) ,intracrevicular incision will be placed with the help of 15c Bard Parker surgical blade , full thickness mucoperiosteal flap will be elevated .
Debridement of granulation tissue will be done and flap will be suture back in position using 3-0 black breaded silk suture, the site will be covered with non eugenol periodontal dressing for protection.
Postoperative instructions will be given to the patient. 2 ml blood will be collected at baseline(sample 1) , at 5 minutes (sample 2) and within 20-30 minutes (sample 3) of starting the procedure
Collection of blood samples Six millilitres (6 ml) of blood samples will be drawn from the patient through an antecubital vein using strict aseptic technique via a 22- gauge sterile plastic cannula and sent for for qPCR analysis to quantify total bacterial load.
PCR ANALYSIS The polymerase chain reaction (PCR) is a laboratory technique for DNA replication that allows the "target" DNA sequence to be selectively amplified. The PCR involves the primer mediated enzymatic amplification of DNA. In this study Quantitive polymerase chain reaction is done.
* DNA from the blood samples will be extracted using the QIAamp DNA Blood Mini Kit according to the manufacture's recommendations.
* In order to quantify the total bacterial load, qPCR will be carried out using a universal primer to the 16S ribosomal RNA gene.
* Analysis was performed in a total volume of 6 ml blood.
* Samples for qPCR will be dispensed into well plates, sealed and centrifuged.
* Amplification will be done , settings for qPCR will be as follows: 95 degree centigrade for 10 minutes followed by 40 amplification cycles at 95 degree centigrade for 1 minute, 52 degree centigrade for 1 minute , 72 degree centigrade for 1 minute.
* After each cycle , PCR products will be monitored for the increase in fluorescence of SYBR green.
* All measurements will be performed in triplicate for both test and controls.
* For the negative control , ultrapure water will be used replacing the clinical sample.
* To determine the specificity of the amplified products, a melting curve will be obtained from 60 degree centigrade to ninty five degree centigrade, with continuous florescence measurement at each 1% increase in temperature.
* Data acquisition and analysis will be performed using the ABI 7500 software.
Statistical analysis Data will be subjected for normality test. Best on the data parametric or non parametric test will be performed. P value \< 0.05 will be considered statistically significant.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: